
25 Jun 2019 Research
Championing groundbreaking therapies and emotional support
The groundbreaking new cell therapy, CAR-T has been offered for the first time on the NHS to eligible patients with non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukaemia (ALL) at King’s College Hospital, London.
CAR-T cell therapy is a pioneering treatment that genetically reprogrammes patients’ immune systems to fight cancer.
Professor Antonio Pagliuca, Professor of Stem Cell Transplantation at King’s College London and Chair of Leukaemia UK’s medical panel, is part of the team which leads on this revolutionary therapy. Commenting on the importance of this development, he said:
“CAR-T is a novel and ground-breaking new cell therapy for certain patients with NHL and ALL. These patients have typically failed to respond to their prior treatments and are now in a very difficult place both physically and emotionally. It is thanks to the innovative Leukaemia UK Mind & Body team at King’s that we are able to support these patients emotionally as well as physically.”
He added: “Thanks to CAR-T therapy, patients appear to be in remission, however we are in the early phases of treatment and the follow-up is short, but we are hopeful that we’re on the right path to finding a cure. This is the start of a new innovative era of therapies and following these promising results, CAR-T therapy will now be rolled out by the NHS for eligible NHL and ALL patients in designated hospitals across the UK.”
Leukaemia UK is also proud to be at the forefront of funding innovative research into gene therapy treatments.
A decade ago, Leukaemia UK funded a substantial research project at King’s College Hospital which allowed researchers to carry out the world’s first trial of combination immune gene therapy to treat leukaemia patients who had reached the end of conventional treatment options.
Our financial support also enabled scientists to pioneer an entirely new vaccination strategy for treatment across a range of leukaemias and solid tumours.
King’s now produces a major proportion of GMP [Good Manufacturing Practice] grade vector for gene therapy programmes in this country and across a number of centres in Europe. These vectors are the genes inserted into cells to force those cells to target bad cells and kill them. This programme is ongoing.
For more news about CAR-T in the media click on BBC News link.
To find out more about our work click here.
Related posts
20 September 2021
Leukaemia charities unite in Blood Cancer Awareness Month to improve diagnosis and the chances of survival
Leading UK leukaemia charities Leukaemia Care and Leukaemia UK have announced a new collaboration to increase awareness of the signs and symptoms of leukaemia and drive improvements in the diagnosis of the disease. The campaign, Spot Leukaemia, is running throughout September – Blood Cancer Awareness Month.
4 April 2022
Leukaemia UK launches search for five new talented Trustees
We are looking for a talented and diverse set of Trustees to join our Board, and help guide the charity as we embark on an ambitious new strategy to accelerate progress in leukaemia research to stop leukaemia devastating lives.
28 November 2022
Leukaemia UK John Goldman Fellow awarded Professorship
Talented blood cancer researcher, Vignir Helgason, was awarded a Leukaemia UK John Goldman Fellowship in 2015, for his research into chronic myeloid leukaemia (CML). Since then, his research career has…
22 May 2023
Can the unique differences between stem cells tell us how well CML treatment will work?
What if we could predict how chronic myeloid leukaemia (CML) patients will respond to treatment? Could the unique signatures of CML stem cells hold the key to personalising treatment for…